Imperial College London

ProfessorMyraMcClure

Faculty of MedicineDepartment of Medicine

Professor of Retrovirology
 
 
 
//

Contact

 

+44 (0)20 7594 3902m.mcclure

 
 
//

Location

 

456Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Publication Type
Year
to

180 results found

Cerrone M, Wang X, Neary M, Weaver C, Fedele S, Day-Weber I, Owen A, Hill A, McClure M, Boffito Met al., 2019, Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals., Clin Infect Dis, Vol: 68, Pages: 446-452

Background: The World Health Organization recommends efavirenz 400 mg (EFV400) as first-line antiretroviral therapy, with a disclaimer that no data with anti-tuberculosis (TB) treatment exist. Many people living with human immunodeficiency virus (PLWH) require TB treatment with isoniazid (INH) and rifampicin (RIF), which affect cytochrome P450 and antiretroviral exposure. Methods: PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a viral load (VL) <50 copies/mL switched to TDF/FTC/EFV400. Genetic polymorphisms and pharmacokinetic (PK) parameters of EFV400 without (PK1) and with INH/RIF following 4 (PK2) and 12 (PK3) weeks of coadministration were evaluated. Results: Twenty-six PLWH were enrolled; 22 completed PK2. All maintained VL <50 copies/mL throughout the study. Geometric mean ratio (GMR) PK2/PK1 of EFV400 maximum plasma concentration (Cmax), area under the curve (AUC), and concentration at 24 hours postdose (C24h) were 0.91 (90% confidence interval [CI], .83-.99), 0.91 (90% CI, .79-1.05), and 0.85 (90% CI, .72-.99), respectively. GMRs (90% CI) of PK3/PK2 and PK3/PK1 Cmax, AUC, and C24h were 0.95 (.86-1.05) and 0.92 (.83-1.01), 0.88 (.75-1.03) and 0.84 (.75-.93), and 0.84 (.72-.99) and 0.75 (.62-.92), respectively. Eleven of 22 participants carried polymorphisms in the CYP2B6 gene associated with slow EFV metabolism. Conclusions: INH/RIF coadministration was associated with limited changes in EFV400 AUC (<25%), and EFV400 concentrations were maintained within ranges of those measured in PLWH in the ENCORE-1 study, irrespective of CYP2B6 genotype. The coadministration of EFV400 with anti-TB treatment can be considered and this is being confirmed in PLWH with TB. Clinical Trials Registration: NCT02832778.

JOURNAL ARTICLE

Elliot ER, Wang X, Singh S, Simmons B, Vera JH, Miller RF, Fitzpatrick C, Moyle G, McClure M, Boffito Met al., 2019, Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition., Clin Infect Dis, Vol: 68, Pages: 87-95

Background: Demographic data show an increasingly aging human immunodeficiency virus (HIV) population worldwide. Recent concerns over dolutegravir-related neuropsychiatric toxicity have emerged, particularly amongst older people living with HIV (PLWH). We describe the pharmacokinetics (PK) of dolutegravir (DTG) 50 mg once daily in PLWH aged 60 and older. Additionally, to address calls for prospective neuropsychiatric toxicodynamic data, we evaluated changes in sleep quality and cognitive functioning in this population after switching to abacavir (ABC)/lamivudine (3TC)/DTG over 6 months. Methods: PLWH ≥60 years with HIV-viral load <50 copies/mL on any non-DTG-based antiretroviral combination were switched to ABC/3TC/DTG. On day 28, 24-hour PK sampling was undertaken. Steady-state PK parameters were compared to a published historical control population aged ≤50 years. We administered 6 validated sleep questionnaires and neurocognitive (Cogstate) testing pre-switch and over 180 days. Results: In total, 43 participants enrolled, and 40 completed the PK phase. Overall, 5 discontinued (2 due to sleep-related adverse events, 4.6%). DTG maximum concentration (Cmax) was significantly higher in patients ≥60 years old versus controls (geometric mean 4246 ng/mL versus 3402 ng/mL, P = .005). In those who completed day 180 (n = 38), sleep impairment (Pittsburgh Sleep Quality Index) was marginally higher at day 28 (P = .02), but not at days 90 or 180. Insomnia, daytime functioning, and fatigue test scores did not change statistically over time. Conclusions: DTG Cmax was significantly higher in older PLWH. Our data provides clinicians with key information on the safety of prescribing DTG in older PLWH.

JOURNAL ARTICLE

Lamorde M, Wang X, Neary M, Bisdomini E, Nakalema S, Byakika-Kibwika P, Mukonzo JK, Khan W, Owen A, McClure M, Boffito Met al., 2018, Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum, CLINICAL INFECTIOUS DISEASES, Vol: 67, Pages: 785-790, ISSN: 1058-4838

JOURNAL ARTICLE

Khurshid S, Govada L, Wills G, McClure MO, Helliwell JR, Chayen NEet al., 2018, Chlamydia protein Pgp3 studied at high resolution in a new crystal form, IUCRJ, Vol: 5, Pages: 439-448, ISSN: 2052-2525

JOURNAL ARTICLE

Wang X, Boffito M, Dickinson L, Bagkeris E, Khoo S, Post F, Mallon P, Vera J, Williams I, Babalis D, Anderson J, McClure M, Winston A, Sabin Cet al., 2018, Plasma NRTI concentrations and renal function in people with HIV, Publisher: WILEY, Pages: S16-S17, ISSN: 1464-2662

CONFERENCE PAPER

Ahmad SF, Brown JK, Campbell LL, Koscielniak M, Oliver C, Wheelhouse N, Entrican G, Mcfee S, Wills GS, McClure MO, Horner PJ, Gaikoumelou S, Lee KF, Critchley HOD, Duncan WC, Horne AWet al., 2018, Pelvic Chlamydial Infection Predisposes to Ectopic Pregnancy by Upregulating Integrin beta 1 to Promote Embryo-tubal Attachment, EBIOMEDICINE, Vol: 29, Pages: 159-165, ISSN: 2352-3964

JOURNAL ARTICLE

Wang X, Nwokolo N, Korologou-Linden R, Hill A, Whitlock G, Day-Weber I, McClure MO, Boffito Met al., 2018, InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes, HIV MEDICINE, Vol: 19, Pages: 1-6, ISSN: 1464-2662

JOURNAL ARTICLE

Singh GKJ, Kaye S, Abbott JC, Boesecke C, Rockstroh J, McClure MO, Nelson Met al., 2018, Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure, HIV CLINICAL TRIALS, Vol: 19, Pages: 46-51, ISSN: 1528-4336

JOURNAL ARTICLE

Sweeney NP, Meng J, Patterson H, Morgan JE, McClure Met al., 2017, Delivery of large transgene cassettes by foamy virus vector, SCIENTIFIC REPORTS, Vol: 7, ISSN: 2045-2322

JOURNAL ARTICLE

Sweeney NP, Meng J, Patterson H, Morgan JE, McClure MO, McClure MOet al., A gene therapy vector for large transgenes-foamy virus vector delivers full-legth dystrophin to muscle derived cells, Nature Scientific Reports

JOURNAL ARTICLE

Aloysius I, Zdravkov J, Whitlock G, Alldis J, Nwokolo N, Aylward A, Arvind A, Wang X, Day-Weber I, McClure M, Boffito M, Smith R, Houghton-Price V, Hill Aet al., 2017, InterPrEP (II): internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London: analysis of safety and outcomes, Publisher: WILEY, Pages: 25-25, ISSN: 1464-2662

CONFERENCE PAPER

Gurrala R, Lang Z, Shepherd L, Davidson D, Harrison E, McClure M, Kaye S, Toumazou C, Cooke GSet al., 2016, Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia, SCIENTIFIC REPORTS, Vol: 6, ISSN: 2045-2322

JOURNAL ARTICLE

Wang X, Nwokolo N, Korologou-Linden R, Hill A, Whitlock G, Day-Weber I, McClure M, Boffito Met al., 2016, InterPrEP: internet-based pre-exposure prophylaxis (PrEP) with generic tenofovir DF/emtricitabine (TDF/FTC) in London -analysis of pharmacokinetics, safety and outcomes, Publisher: INT AIDS SOCIETY, ISSN: 1758-2652

CONFERENCE PAPER

Sweeney NP, Regan C, Liu J, Galleu A, Dazzi F, Lindemann D, Rupar CA, McClure MOet al., 2016, Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector, MOLECULAR THERAPY, Vol: 24, Pages: 1227-1236, ISSN: 1525-0016

JOURNAL ARTICLE

Bissett SL, 2016, HPV vaccine-induced cross-neutralising antibodies target complex epitopes on the major capsid protein

The current human papillomavirus (HPV) vaccines consist of major capsid protein (L1) virus-like particles (VLP) and target the two most prevalent oncogenic genotypes, HPV16 and HPV18. Prophylactic HPV vaccination is highly effective at preventing HPV16 and HPV18 infection and associated cervical disease, with type-specific neutralising antibodies thought to be the immune mediators of vaccine type protection. A degree of vaccine-induced cross-protection has also been demonstrated against genetically-related genotypes in the Alpha-7 (HPV18-like) and Alpha-9 (HPV16-like) species groups and although the underlying immune mechanism is uncertain, cross-protection is coincident with the detection of cross-neutralising antibodies. The aim of this thesis was to delineate the HPV L1 domains that are recognised by inter-genotype cross-neutralising antibodies. The formal analysis of the vaccine-induced A9 L1 antibody response demonstrated that cross-neutralising antibodies were a minor component of the total HPV16 antibody response and comprised antibody specificities which recognised single and multiple non-vaccine genotypes. The bioinformatic examination of A9 capsid amino acid sequences demonstrated that the L1L2 pseudovirions (PsV) used to measure cross-neutralising responses were generally representative of available contemporary sequences. The potential impact of amino acid variation within the L1 capsid protein was investigated for HPV31 and found differences in cross-neutralising antibody recognition of the L1 variants; however, this was of a low magnitude. L1 crystallographic homology models predicted structural changes in the loops between HPV16 and the non-vaccine A9 genotypes, informing the design and generation of chimeric PsV with inter-genotype loop swaps. These chimeric PsV demonstrated that cross-neutralising antibodies recognise DE and FG loop amino acid residues within close proximity to each other on the capsid surface. These data contribute to our understan

THESIS DISSERTATION

Wang X, Penchala SD, Amara A, Else L, McClure M, Boffito Met al., 2016, A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection, THERAPEUTIC DRUG MONITORING, Vol: 38, Pages: 327-331, ISSN: 0163-4356

JOURNAL ARTICLE

Singh G, Nelson M, Hicks G, McClure M, Kaye S, Boesecke C, Rockstroh Jet al., 2016, Baseline telaprevir (TVR) resistance mutations do not predict failure in the response guided treatment of genotype 1 acute hepatitis C (HCV) in individuals with HIV co-infection, HIV MEDICINE, Vol: 17, Pages: 26-26, ISSN: 1464-2662

JOURNAL ARTICLE

Quinn K, Winston A, Kaye S, Maertens G, McClure M, Cortese R, Pessi Aet al., 2016, Slow emergence of resistance to C34-PEG4-Chol; a novel HIV fusion inhibitor, Publisher: WILEY-BLACKWELL, Pages: 29-29, ISSN: 1464-2662

CONFERENCE PAPER

Horner PJ, Wills GS, Righarts A, Vieira S, Kounali D, Samuel D, Winston A, Muir D, Dickson NP, McClure MOet al., 2016, Chlamydia trachomatis Pgp3 Antibody Persists and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study, PLOS ONE, Vol: 11, ISSN: 1932-6203

JOURNAL ARTICLE

Erlwein O, Sweeney NP, de Leon R, Wills G, Robinson MJ, McClure MOet al., 2016, Determination of Sequences Required for Human Endogenous Retrovirus K Transduction and Its Recognition by Foreign Retroviral Virions, JOURNAL OF VIROLOGY, Vol: 90, Pages: 3243-3246, ISSN: 0022-538X

JOURNAL ARTICLE

Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO, Kellam P, Pybus OGet al., 2015, Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals, PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, Vol: 370, ISSN: 0962-8436

JOURNAL ARTICLE

Thompson CC, Griffiths C, Nicod SS, Lowden NM, Wigneshweraraj S, Fisher DJ, McClure MOet al., 2015, The Rsb Phosphoregulatory Network Controls Availability of the Primary Sigma Factor in Chlamydia trachomatis and Influences the Kinetics of Growth and Development, PLOS PATHOGENS, Vol: 11, ISSN: 1553-7366

JOURNAL ARTICLE

Hamlyn E, Stoehr W, Cooper DA, Fisher M, Tambussi G, Schechter M, Miro JM, Vanobberghen F, Babiker A, Weber J, Mcclure M, Porter K, Fidler Set al., 2015, The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels, AIDS, Vol: 29, Pages: 1355-1361, ISSN: 0269-9370

JOURNAL ARTICLE

Martin TCS, Singh GJ, McClure M, Nelson Met al., 2015, HCV Reinfection Among HIV-Positive Men Who Have Sex With Men: A Pragmatic Approach, HEPATOLOGY, Vol: 61, Pages: 1437-1437, ISSN: 0270-9139

JOURNAL ARTICLE

Tipple C, Jones R, McClure M, Taylor Get al., 2015, Rapid Treponema pallidum Clearance from Blood and Ulcer Samples following Single Dose Benzathine Penicillin Treatment of Early Syphilis, PLOS NEGLECTED TROPICAL DISEASES, Vol: 9, ISSN: 1935-2735

JOURNAL ARTICLE

Nye LC, Gray N, McClure M, Boffit M, Holmes E, Plumb RS, Wilson IDet al., 2015, Identification of a novel human circulating metabolite of tenofovir disoproxil fumarate with LC-MS/MS, BIOANALYSIS, Vol: 7, Pages: 643-652, ISSN: 1757-6180

JOURNAL ARTICLE

Berkhout B, Bodem J, Erlwein O, Herchenroeder O, Khan AS, Lever AML, Lindemann D, Linial ML, Loechelt M, McClure MO, Scheller C, Weiss RAet al., 2014, Obituary: Axel Rethwilm (1959-2014), RETROVIROLOGY, Vol: 11, ISSN: 1742-4690

JOURNAL ARTICLE

Hamlyn E, Fidler S, Stoehr W, Cooper DA, Tambussi G, Schechter M, Miro JM, Mcclure M, Weber J, Babiker A, Porter Ket al., 2014, Interleukin-6 and D- dimer levels at seroconversion as predictors of HIV-1 disease progression, AIDS, Vol: 28, Pages: 869-874, ISSN: 0269-9370

JOURNAL ARTICLE

Stoehr W, Fidler S, McClure M, Weber J, Cooper D, Ramjee G, Kaleebu P, Tambussi G, Schechter M, Babiker A, Phillips RE, Porter K, Frater Jet al., 2013, Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy, PLOS ONE, Vol: 8, ISSN: 1932-6203

JOURNAL ARTICLE

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00104514&limit=30&person=true